PGR, progesterone receptor, 5241

N. diseases: 392; N. variants: 33
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker group BEFREE The most common breast cancer type was adenocarcinomas (59.1%) and half of the breast cancers were hormone sensitive, with estrogen receptor positive status in 10 of 19 tested and progesterone receptor positive status in 5 of 14 tested. 30087072 2018
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker group BEFREE Therefore, the aim of the current study was to evaluate cell death induced by curcumin and paclitaxel alone and in combination in human breast cancer cell lines: MCF7, an epithelial and luminal-like adenocarcinoma cell line triple positive for estrogen and progesterone receptor, and MDA-MB-234, a metastatic human breast cancer cell line triple negative for such receptors, as well as MCF-10F as a normal breast cell line. 30066930 2018
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker group BEFREE Using a script written in R, the diagnostic accuracy of all possible combinations of markers was evaluated and it was shown that a 3 marker panel including vimentin, ER, or PR, and an HPV marker (p16, ProExC, or HPV ISH) is optimal for determining site of origin for usual endometrial and endocervical adenocarcinomas. 20534993 2010
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker group BEFREE We compared expression of ERs, progesterone receptor (PR) and cyclooxygenase-2 (COX-2) in stage 1 endometrial adenocarcinomas graded as well (G1), moderately (G2) or poorly (G3) differentiated (n >or= 10 each group) using qRTPCR, single and double immunohistochemistry. 19758455 2009
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 AlteredExpression group BEFREE Using multiple antibodies, we investigated the immunohistochemical expression of estrogen receptors alpha and beta and progesterone receptor in 317 NSCLCs placed in tissue microarrays and correlated their expression with patients' clinicopathologic characteristics and in adenocarcinomas with EGFR mutation status. 19706809 2009
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 AlteredExpression group BEFREE Tumors were poorly differentiated ER-alpha and progesterone receptor-negative adenocarcinomas that expressed keratins, EMA, and E-cadherin. 16873885 2006
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 AlteredExpression group BEFREE Progesterone receptor (PR) expression was increased by E(2) in two out of five adenocarcinoma cell lines from females, but none from males. 16601283 2006
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker group BEFREE Immunohistochemical evaluation of androgen receptor (AR), estrogen receptor-alpha (ER-alpha), estrogen receptor-beta (ER-beta), and progesterone receptor (PR) was carried out in prostate needle biopsies obtained before and after radiotherapy from 60 patients with adenocarcinoma. 15900599 2005
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker group CTD_human Distinct DNA methylation profiles in malignant mesothelioma, lung adenocarcinoma, and non-tumor lung. 15639718 2005
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker group BEFREE Mifepristone effectively inhibited the proliferation of PR-positive human gastric adenocarcinoma cell line SGC-7901 in vitro through multiple mechanisms, and may be a beneficial agent against human adenocarcinoma. 15309708 2004
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 GeneticVariation group BEFREE While the exon 4-deleted, exon 6-deleted and exon 3,4-deleted PR variant mRNAs were observed in all samples analyzed, the exon 5,6-deleted, exon 4,5,6-deleted and/or exon 3,4,5,6-deleted PR variant mRNAs could not be detected in some cases, especially in poorly differentiated adenocarcinoma as compared with well-differentiated and moderately differentiated adenocarcinomas. 10644942 2000
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 AlteredExpression group BEFREE The results of this study show that bcl-2 is relatively highly expressed in proliferative (n = 11) and hyperplastic (n = 18) endometrium, with respective mean staining scores of 3.59 and 3.47 (scale, 0-4), but is significantly (P < 0.001) down-regulated in atypical hyperplasia (n = 11; score, 0.82), and adenocarcinoma (n = 34; score, 0.86). bcl-2 expression did not correlate with stage, grade, estrogen-receptor, or progesterone-receptor expression. 8729985 1996
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 AlteredExpression group BEFREE In summary, lactoferrin is expressed in a region of normal endometrium known as the zona basalis which is not shed with menstruation and is frequently overexpressed by progesterone receptor-negative cells in endometrial adenocarcinomas. 7867003 1995
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 AlteredExpression group BEFREE We determined DNA content, S-phase fraction, and estrogen (ER) und progesterone receptor (PR) levels in 36 stage I endometrial adenocarcinomas and in 22 hyperplastic lesions to obtain information on the genesis and progression of endometrial malignancy. 8491764 1993
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker group BEFREE Sixty-five percent (53/82) of ovarian adenocarcinomas, 57% (8/14) of benign/borderline tumours and only 31% (5/16) of normal ovarian tissues studied showed specific 125I-EGF (epidermal growth factor) binding (median: 17; 10; and 0 fmol EGF-R/mg protein, respectively) and a significant increase in progesterone receptor (PgR) levels was observed in these groups (median: 5; 33; and 152 fmol/mg protein, respectively). 1325950 1992